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Abstract
Purpose Antiemetic guidelines recommend co-administration
of targeted prophylactic medications inhibiting molecular path-
ways involved in emesis. NEPA is a fixed oral combination of a
newNK1 receptor antagonist (RA), netupitant (NETU 300mg),
and palonosetron (PALO 0.50 mg), a pharmacologically dis-
tinct 5-HT3 RA. NEPA showed superior prevention of
chemotherapy-induced nausea and vomiting (CINV) compared
with oral PALO in a single chemotherapy cycle; maintenance
of efficacy/safety over continuing cycles is the objective of this
study.
Methods This study is a multinational, double-blind study
comparing a single oral dose of NEPA vs oral PALO in
chemotherapy-naïve patients receiving anthracycline/
cyclophosphamide-based chemotherapy along with dexa-
methasone 12 mg (NEPA) or 20 mg (PALO) on day 1.
The primary efficacy endpoint was delayed (25–120 h)
complete response (CR: no emesis, no rescue medication)
in cycle 1. Sustained efficacy was evaluated during the
multicycle extension by calculating the proportion of pa-
tients with overall (0–120 h) CR in cycles 2–4 and by
assessing the probability of sustained CR over multiple
cycles.
Results Of 1455 patients randomized, 1286 (88 %) partic-
ipated in the multiple-cycle extension for a total of
5969 cycles; 76 % completed ≥4 cycles. The proportion
of patients with an overall CR was significantly greater for
NEPA than oral PALO for cycles 1–4 (74.3 vs 66.6 %,
80.3 vs 66.7 %, 83.8 vs 70.3 %, and 83.8 vs 74.6 %,
respectively; p ≤ 0.001 each cycle). The cumulative per-
centage of patients with a sustained CR over all 4 cycles
was also greater for NEPA (p < 0.0001). NEPA was well
tolerated over cycles.
Conclusions NEPA, a convenient, guideline-consistent, fixed
antiemetic combination is effective and safe over multiple
cycles of chemotherapy.
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A prior publication reported the cycle 1 findings of this study [Aapro
et al., Annals of Oncology 2014 NCT01339260]. This paper focuses on
the findings in the multiple-cycle extension, data which was an oral pre-
sentation at both the ASCO and MASCC Annual Meetings in 2014.
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Introduction
International guideline committees consistently recommend
combination antiemetic regimens targetingmultiple molecular
pathways associated with emesis as the standard of care for
prevention of chemotherapy-induced nausea and vomiting
(CINV) [1, 2]. Antiemetic guidelines currently recommend a
prophylactic combination of a 5-HT3 receptor antagonist
(RA), a neurokinin-1 (NK1) RA, and dexamethasone when
administering highly emetogenic chemotherapy (HEC) or
anthracycline-cyclophosphamide chemotherapy, as studies
have shown a clear benefit with the addition of an NK1 RA
to the standard 5-HT3 RA plus dexamethasone regimen in
these settings [1, 2].
Unfortunately, adherence to antiemetic guidelines is sub-
optimal, despite continued research suggesting that guideline
conformity improves CINV control for patients [3–5].
Consequently, even with effective agents available, many pa-
tients still suffer from CINV [6]. The supportive care commu-
nity, in particular, continues to evaluate opportunities to rein-
force and encourage implementation of guidelines into clinical
practice, as well as monitor adherence.
Netupitant (NETU) is a new highly selective NK1 RA
which has been developed as an oral fixed combination with
palonosetron (referred to as NEPA; AKYNZEO®).
Palonosetron was specifically chosen as the 5-HT3 RA for
the NEPA combination because of its distinct pharmacologi-
cal [7] and clinical [6] characteristics. Palonosetron is distin-
guished from the older 5-HT3 RAs in the class with its unique
receptor binding, its ability to inhibit the cross talk between
the 5-HT3 and NK1 receptors, its ability to induce NK1 recep-
tor internalization and to work synergistically with NETU to
enhance the inhibition of the substance P response, in addition
to its distinctly better efficacy during the delayed (25–120 h)
phase [7–9]. Consequently, it has the potential to enhance
prevention of delayed CINV when used in combination with
NETU. The NEPA combination also has the potential to im-
prove guideline adherence by targeting two critical pathways
involved in emesis with a convenient, single oral dose.
In a phase 2 single-cycle, dose-ranging study [10] in pa-
tients receiving HEC, the NEPA oral combination of NETU
300 mg + PALO 0.50 mg was shown to be superior to oral
palonosetron during the delayed and overall (0–120 h) phases
for all efficacy endpoints.
The current phase 3 study was designed to demonstrate
superior prevention of CINV during cycle 1 with oral NEPA
compared with oral palonosetron in patients receiving
anthracycline-cyclophosphamide chemotherapy (and to eval-
uate NEPA’s safety). This study was also designed to evaluate
whether the efficacy (and safety) seen in cycle 1 would be
preserved over continuing treatment cycles. In a previously
reported phase 3 study, NEPAwas shown to be well tolerated
over multiple cycles of HEC and moderately emetogenic
chemotherapy (MEC) [11]. In the limited number of trials
evaluating the multicycle efficacy of antiemetics, interpreta-
tion of the results has been challenging due to high dropout
rates and differing statistical methods utilized [12]. As preser-
vation of benefit over repeated cycles of chemotherapy is es-
sential for optimal supportive care during cancer treatment,
antiemetics need to be able to demonstrate a sustained benefit.
The cycle 1 data has been previously reported by Aapro
et al. [13]; a single oral dose of NEPA plus dexamethasone
prior to chemotherapy resulted in superior complete response
(no emesis, no rescue medication) rates during the delayed
phase (primary endpoint) compared with oral palonosetron
plus dexamethasone. The efficacy of NEPA was supported
by consistent superiority over oral palonosetron for all second-
ary efficacy endpoints (i.e., no emesis, no significant nausea,
complete protection) during both the delayed and overall
phases. This publication reports the results of the multiple-
cycle extension of this study.
Materials and methods
Study design
This study was conducted between April 2011 and November
2012 in accordance with GCP, ICH, Declaration of Helsinki
principles, and local laws and regulations. Protocol approval
was obtained from ethical review committees for each site,
and written informed consent was obtained from each patient
before enrollment. The study design has been described in
detail in the cycle 1 publication [13]. After completion of
cycle 1, patients had the option to participate in a multiple-
cycle extension, receiving the same treatment as assigned in
cycle 1 for as long as they continued to fulfill the inclusion/
exclusion criteria. There was no pre-specified limit of the
number of repeat consecutive cycles. Patients received one
of the following two treatments: oral NEPA (NETU 300 mg/
PALO 0.50 mg) plus 12 mg dexamethasone or oral
palonosetron 0.50 mg plus 20 mg dexamethasone, all given
prior to chemotherapy each cycle.
Eligibility criteria
Eligible patients were ≥18 years, naïve to chemotherapy, and
scheduled to receive their first course of an anthracycline/
cyclophosphamide regimen for treatment of a solid malignant
tumor. The chemotherapy consisted of either cyclophospha-
mide IV (500 to 1500 mg/m2) and doxorubicin IV (≥40 mg/
m2) or cyclophosphamide IV (500 to 1500 mg/m2) and
epirubicin IV (≥60 mg/m2). Patients were required to have
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0, 1, or 2. Patients were not eligible if they
were scheduled to receive (1) HEC from days 1 to 5 or MEC
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from days 2 to 5 following chemotherapy, (2) radiation thera-
py to the abdomen or pelvis within 1 week prior to day 1 or
between days 1 and 5, or (3) a bone marrow or stem cell
transplant. Patients were not allowed to receive any drug with
known or potential antiemetic efficacy within 24 h prior to day
1 and were excluded if they experienced any vomiting,
retching, or mild nausea within 24 h prior to day 1. Patients
were not to have had any serious cardiovascular disease his-
tory or predisposition to cardiac conduction abnormalities,
with the exception of incomplete right bundle branch block.
Because netupitant is a moderate inhibitor of CYP3A4, use of
any CYP3A4 inducer within 4 weeks, use of a strong or mod-
erate inhibitor within 1 week, or scheduled to receive CYP3A4
inhibitors, inducers, or certain substrates as concomitant medi-
cation were prohibited. For each cycle of the multiple-cycle
extension, the investigator needed to consider it appropriate
and not posing any unwarranted risk to the patient. There was
to have been satisfactory study compliance in the preceding
chemotherapy cycle, and patients were to be scheduled to re-
ceive the same chemotherapy regimen as cycle 1.
Assessments and statistical methods
From the start of chemotherapy infusion on day 1 through the
morning of day 6 (0–120 h) of each cycle, patients completed
a diary, capturing information pertaining to occurrence and
timing of each emetic episode and rescue medication intake.
Metoclopramide tablets were provided as rescue medication;
however, the investigator was allowed to use an alternative
rescue (excluding 5-HT3 or NK1 RAs, as well as
palonosetron) at his/her discretion. The use of rescue medica-
tion for treatment of either nausea or vomiting was considered
treatment failure. Severity of nausea was evaluated daily by
patients in the diary by using a 100-mm horizontal visual
analog scale (VAS). The left end of the scale (0 mm) was
labeled as “no nausea,” and the right end of the scale
(100 mm) was labeled as “nausea as bad as it could be.” No
significant nausea was defined as a maximum score <25 mm.
The objective of the multiple-cycle extension was to com-
pare the efficacy and safety of oral NEPA relative to oral
palonosetron across multiple cycles of chemotherapy. The pri-
mary aim of the study was to demonstrate the superiority of
NEPA over oral palonosetron based on the proportion of pa-
tients with a CR during the delayed (25–120 h) phase of cycle
1. In the multiple-cycle extension, the proportion of patients
with CR and no significant nausea were prospectively defined
efficacy endpoints, but no formal comparisons between
groups were pre-specified. Thus, p values for the multiple-
cycle extension should only be descriptively interpreted. CR,
no emesis, and no significant nausea rates were compared by
using a two-sided Cochran-Mantel-Haenszel (CMH) test in-
cluding treatment, age class, and region as strata. A separate
analysis of sustained CR evaluated the probability that a
patient would remain a complete responder over 4 cycles of
chemotherapy. This analysis was performed by using Kaplan-
Meier methods, and patients who did not sustain a CR were
considered treatment failures. Treatment groups were com-
pared via a log-rank test. As the majority of patients had com-
pleted their planned chemotherapy after 4 cycles of treatment
(as expected in “standard” AC protocols), only 36 % of pa-
tients received a fifth cycle and 27 % a sixth cycle; therefore,
efficacy data is only presented through cycle 4.
Safety was assessed primarily by a clinical review of
treatment-emergent adverse events. The multiple-cycle exten-
sion summarized incidence rates for cycles 2–6, while cycle 1
was evaluated separately. Cardiac safety was evaluated by car-
diac adverse events, electrocardiogram (ECG) changes (includ-
ing QTc), cardiac troponin levels, and left ventricular ejection
fraction (LVEF). During each cycle, ECGs were recorded pre-
dose and 5, 24, and 120 h post-dose. Troponin levels (cTnI)
were measured pre-dose and 24 and 120 h post-dose of each
cycle by using a standardized troponin assay (Siemens’
ADVIA Centaur TnI-Ultra troponin assay). A threshold of
0.12 ng/mL was considered an “alert value” [14]. LVEF was
assessed for all patients at visit 1 and at the end of the study. No
formal comparisons were performed for the safety assessments.
Results
A total of 1455 patients were randomized into the study. Of
these, 1286 patients (88.4 %) entered the multiple-cycle ex-
tension, 167 patients did not enter the extension, and 4 patients
did not receive the protocol-required chemotherapy or study
drug in cycle 2 (Fig. 1). Patients participated in a total of 5969
chemotherapy cycles with 76 % of all patients (76 % NEPA,
77 % palonosetron) completing at least 4 cycles; 27 % of all
patients completed 6 cycles.
Baseline and disease characteristics and emetic risk factors
for patients entering the multiple-cycle extension are listed in
Table 1 and are similar to those reported previously for pa-
tients in cycle 1. Treatment groups were similar and consistent
with a cancer population receiving the protocol-specified
anthracycline-cyclophosphamide chemotherapy regimen.
Almost all patients were female with breast cancer (98 %);
the majority were white (78 %), and the median age was
54 years. All patients but one (99.9 %) were treated with
cyclophosphamide plus an anthracycline (65 % doxorubicin
and 35% epirubicin). Doses of these chemotherapeutic agents
were similar at baseline and remained consistent for subse-
quent cycles.
Efficacy
The proportion of patients with an overall (0–120 h) CR
was significantly greater for NEPA compared with oral
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palonosetron during cycle 1, and this was maintained in
subsequent cycles (Fig. 2). The incremental benefit of
NEPA over oral palonosetron in cycles 2–4 was greater than
that seen in cycle 1 (7.7 % in cycle 1, 13.6 % in cycle 2,
13.5 % in cycle 3, and 9.2 % in cycle 4). CR rates were
similar for NEPA and oral palonosetron during the acute
Fig. 1 Consort diagram of the
disposition of patients
Table 1 Baseline and disease
characteristics for patients
participating in the multiple-cycle
extension
Characteristic NEPA + DEX (N = 635) Oral PALO + DEX (N = 651)
Gender (%)
Female 98.3 98.0
Male 1.7 2.0
Median age (years) 54.0 54.0
Ethnic group (%)
White 77.3 79.0
Asian 15.6 15.2
Hispanic 6.6 5.4
Black 0.2 0.2
Other 0.3 0.3
Cancer type (%)
Breast 97.8 97.7
Other 2.2 2.3
ECOG performance status (%)
0 68.7 68.5
1 30.7 31.3
2 0.6 0.2
Alcohol consumption (%)
No 80.9 81.3
Occasionally 18.7 18.1
Regularly 0.3 0.6
Chemotherapy (%)
Cyclophosphamide 99.8 100
Doxorubicin 67.2 63.0
Epirubicin 32.8 37.0
Mean total dose (mg)
Cyclophosphamide 987.7 986.4
Doxorubicin 97.7 98.3
Epirubicin 131.2 131.1
NEPA netupitant/palonosetron, PALO palonosetron, DEX dexamethasone, ECOG Eastern Cooperative Oncology
Group
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phase but higher for NEPA compared with ora l
palonosetron during the delayed phase.
The percentage of patients who experienced a CR in cycle
1 and who sustained a CR over cycles 2–4 was significantly
greater for NEPA than with oral palonosetron (p < 0.001,
based on log-rank test) (Fig. 3). The absolute difference be-
tween NEPA and oral palonosetron in percentage of patients
sustaining a CR continued to increase over time.
NEPA was also consistently more effective than oral
palonosetron in preventing emesis and significant nausea over
cycles 1–4 (Table 2). The percentage of patientswho experienced
no significant nausea in cycle 1 and who sustained this nausea
control over cycles 2–4 was significantly greater for NEPA than
oral palonosetron (p = 0.035, based on log-rank test) (Fig. 4).
Safety
Adverse events
The overall incidence, type, frequency, and intensity of
treatment-emergent adverse events were comparable between
the two treatment groups during the multiple-cycle extension
(Table 3). There was no increase in incidence rates of adverse
events across cycles, whether treatment-related or not (Table 4).
Fig. 2 Overall (0–120 h)
complete response (no emesis, no
rescue medication) rates
Fig. 3 Sustained overall (0–
120 h) complete response over
cycles 1–4: Kaplan-Meier curve
of continued CR success rate.
Patients who did not sustain a CR
were considered treatment
failures
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Among the patients reporting adverse events during the
multiple-cycle extension, the majority (85 %) reported adverse
events of mild/moderate intensity. Of the 98 (15 %) NEPA-
treated patients who experienced a severe adverse event, only
1 patient had a severe event considered to be treatment-related.
The most common treatment-related adverse events were head-
ache (3.5 % NEPA, 2.8 % oral palonosetron) and constipation
(2.0 % NEPA, 2.2 % oral palonosetron). There were no serious
treatment-related adverse events during cycle 1 or during the
multiple-cycle extension for either treatment group. There were
also no treatment-related adverse events leading to discontinu-
ation and no deaths for NEPA-treated patients.
Cardiac safety
The percentage of patients with at least one adverse event clas-
sified as a cardiac disorder was similar for both groups in cycle
1 (2.6 % NEPA, 2.1 % oral palonosetron) and during the
multicycle extension (5.0 % NEPA, 4.6 % oral palonosetron).
The percent of patients with treatment-emergent ECG abnor-
malities was comparable between groups. The mean changes in
QTcF were small and similar between groups and returned to
baseline at 120 h. The percentage of patients with increases
from baseline of >60 ms in QTcF were 0.7 and 1.1 % for
NEPA and oral palonosetron, respectively, for cycle 1 and 1.5
and 2.6 % in the multiple-cycle extension. Similar proportions
of patients had high troponin levels (i.e., >0.12 ng/mL) in cycle
1 (0.1 % NEPA vs 0.3 % oral palonosetron) and in the
multicycle extension (3.4 %NEPAvs 2.9 % oral palonosetron).
Of these, 0.4 % NEPA and 0.7 % oral palonosetron had tropo-
nin values greater than 0.50 ng/mL. In the majority of cases, the
high values developed in cycles 5 and 6. Mean LVEF changes
from screening to end of study were negligible and comparable
between groups.
Table 2 Overall (0–120 h) no emesis and no significant nausea rates
% of patients
(N = NEPA/PALO)
No emesis No significant nauseab
NEPA + DEX Oral PALO + DEX Absolute
difference
p valuea NEPA + DEX Oral PALO + DEX Absolute
difference
p valuea
Cycle 1 (N = 724/725) 79.8 72.1 7.7 <0.001 74.6 69.1 5.5 0.020
Cycle 2 (N = 635/651) 85.5 73.7 11.8 <0.0001 77.3 71.6 5.7 0.018
Cycle 3 (N = 598/606) 88.3 77.2 11.1 <0.0001 78.4 73.3 5.1 0.034
Cycle 4 (N = 551/560) 87.3 79.5 7.8 0.0003 80.2 75.2 5.0 0.042
NEPA netupitant/palonosetron, PALO palonosetron, DEX dexamethasone
a Pre-specified for cycle 1, post hoc for cycles 2–4; not adjusted for multiple comparisons
bDefined as maximum nausea score <25 mm on 100-mm visual analog scale
Fig. 4 Sustained overall (0–
120 h) no significant nausea over
cycles 1–4: Kaplan-Meier curve
of continued nausea control.
Patients who did not sustain
nausea control were considered
treatment failures
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Discussion
The presence of CINV in the first cycle of chemotherapy has
been established as a strong predictor of CINV in subsequent
cycles [15, 16]. Therefore, the best available prophylactic anti-
emetics should be administered beginning at the first course of
chemotherapy to maximize prevention of CINV from the start.
All antiemetic guideline committees consistently suggest that
combination regimens aimed at multiple molecular targets as-
sociatedwith emesis are now the standard of care for prevention
of HEC and some types of MEC-induced CINV [1, 2].
Developed as the first antiemetic combination agent, NEPA
presents a convenient approach to targeting what experts now
believe are the two most important molecular targets (sub-
stance P/NK1 and serotonin/5-HT3) associated with CINV
[6]. In this study, NEPAwas administered with a single dose
of dexamethasone. This offers a simple single-day “triplet”
regimen and could reduce side effects associated with
multiple-day dosing of dexamethasone.
This study evaluated 1450 patients over a total of almost
6000 chemotherapy cycles. While historically, the high drop-
out rate in multicycle trials has created methodologic
challenges, in this study, 76 % of all patients completed at
least 4 cycles of chemotherapy. The population selected in-
cluded patients with solid tumors receiving an anthracycline-
cyclophosphamide chemotherapy regimen. This combination
has historically been considered a moderately emetogenic reg-
imen but because it is commonly administered to (young)
females with breast cancer (as was the case in this study),
the emetogenic risk is substantially increased due to the addi-
tional patient-related risk factors [1, 2]. Consequently, the
population evaluated in this study represents a group at sig-
nificant risk for CINV. All antiemetic guidelines recommend
NK1 RA/5-HT3RA/dexamethasone prophylaxis in this setting
with guideline committees now classifying anthracycline-
cyclophosphamide regimens as HEC. However, if an NK1
RA is not available, the Multinational Association for
Supportive Care in Cancer (MASCC) recommends the use
of palonosetron as the preferred 5-HT3 RA [2].
While this study was conducted in a relatively homogenous
population of predominantly white females, other studies in
the NEPA program have demonstrated efficacy and safety in a
broader population of patients receiving various types of
emetogenic chemotherapy [10, 11].
Table 3 Summary of most
common (≥5 %) adverse eventsa
during the multiple-cycle
extension
% of patients with NEPA + DEX (N = 635) Oral PALO + DEX (N = 651)
Neutropenia 35.6 36.6
Alopecia 23.9 23.2
Leukopenia 21.7 21.7
Asthenia 11.0 10.6
Headache 8.3 8.8
Fatigue 7.7 7.5
Anemia 7.4 6.3
Hyperglycemia 7.1 6.6
Diarrhea 5.2 3.2
Decreased appetite 4.4 6.5
Constipation 4.3 5.1
Nausea 4.3 5.4
NEPA netupitant/palonosetron, PALO palonosetron, DEX dexamethasone
aAll treatment-emergent adverse events whether deemed to be treatment-related or not
Table 4 Incidence of adverse
events across cycles % of patients with
adverse event
Treatment-emergent
adverse event
Treatment-related
adverse event
Cycle (N = NEPA/PALO) NEPA + DEX Oral PALO + DEX NEPA + DEX Oral PALO + DEX
Cycle 1 (N = 725/725) 76.0 69.9 8.1 7.2
Cycle 2 (N = 635/651) 65.0 61.4 6.5 4.5
Cycle 3 (N = 598/605) 57.4 53.2 3.5 3.5
Cycle 4 (N = 550/561) 46.4 39.0 4.0 1.2
Cycle 5 (N = 271/249) 40.6 39.8 2.6 0.8
Cycle 6 (N = 197/191) 31.0 30.9 1.5 0.5
NEPA netupitant/palonosetron, PALO palonosetron, DEX dexamethasone
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The data supporting the sustained efficacy benefit of NEPA
over multiple cycles in this study is compelling for clinical prac-
tice. The NEPA benefit over oral palonosetron was maintained
over multiple cycles for overall complete response rates and also
for no emesis and no significant nausea in each cycle. These
findings were consistent for all endpoints across the entire period
of risk (0–120 h) for all four chemotherapy cycles.
Nausea remains a clinical challenge, and the nausea control
rates were not as high as those for emesis. However, it is encour-
aging that treatment including NEPA resulted in a clinical benefit
over oral palonosetron in preventing significant nausea over mul-
tiple cycles, as there have been no consistent findings to date
supporting the role of other NK1 receptor antagonists in nausea
control [17–21]. These results are supported by a prior phase 2 trial
where NEPA resulted in superior nausea control over oral
palonosetron in patients receiving highly emetogenic chemothera-
py [10].
A complementary analysis offers perhaps a more rigorous ap-
proach to assessing preservation of efficacy in that it evaluates
continued CR success over multiple cycles by censoring those
patients who had emesis or more than mild nausea (i.e., CR fail-
ures); this approach was utilized previously in analyzing the
sustained benefit of aprepitant over multiple cycles in a similar
population of patients receiving AC chemotherapy [12]. In this
study, the complementary analysis demonstrated significantly
more NEPA-treated patients having continued CR success across
cycles (log-rank test, p < 0.0001). It is notable that the incremental
benefit of NEPA over oral palonosetron continued to increase
across cycles with 13 % more NEPA-treated patients having con-
tinued CR by cycle 4. Similar results were seen for sustained
nausea control (Fig. 4).
These findings are particularly impressive considering that
NEPA (plus dexamethasone) was compared with and shown to
be superior to oral palonosetron, the MASCC guideline-preferred
5-HT3 RA (plus dexamethasone) in the setting when an NK1 RA
is unavailable. This suggests that the incremental benefit of the
NEPA combination over an older 5-HT3 RA might be greater.
Future trials could be considered to explore this as well as evalu-
ating how NEPAwould perform against an aprepitant-containing
regimen. According to the data generated thus far, NEPA showed
slightly higher response rates than an exploratory aprepitant arm in
both a single-cycle study in patients receiving highly emetogenic
chemotherapy [10] and over multiple cycles in patients receiving
either non-AC moderately or highly emetogenic chemotherapy
[13].
Consistent with the safety findings previously reported in cycle
1 of this study [13] and in the HEC/MECmultiple-cycle trial [11],
NEPA was well tolerated over multiple cycles of chemotherapy
without evidence for increasing adverse events over time/cycles or
cardiac safety concerns for either agent. There continued to be a
low incidence of treatment-related adverse events, none of which
led to discontinuation, and there were no serious treatment-related
adverse events or deaths for NEPA-treated patients.
Conclusion
The results of this study demonstrate superiority of NEPA over oral
palonosetron (both givenwith dexamethasone) in preventing CINV
and sustained efficacy over multiple cycles of chemotherapy. As a
novel antiemetic combining a new NK1 RAwith palonosetron (the
guideline “preferred” 5-HT3 RA), NEPA offers promising efficacy
with guideline-consistent antiemetic prophylaxis and may represent
an advance in antiemetic treatment options.
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